注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Inhibikase Therapeutics Inc是一家臨床階段的製藥公司。該公司專注於開發帕金森病(PD)以及大腦內外發生的相關紊亂的治療方法。該公司的候選產品包括IkT-148009、IkT-001pro和IKT-01427。其主要候選產品IkT-148009是一種腦滲透性Abelson酪氨酸激酶(c-Abl)抑製劑,可阻止疾病進展並逆轉大腦功能喪失和胃腸道(GI)神經功能障礙。其IkT-148009用於治療PD,包括其在胃腸道中的表現。其候選產品IKT-001Pro是抗癌藥伊馬替尼的前藥,該藥物用於治療慢性骨髓性白血病(CML)。IKT-01427是一種口服腦滲透藥物,旨在阻止約翰坎寧安(JC)病毒進入細胞,從而阻止其在體內復制的能力。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Milton H. Werner | 59 | 2010 | CEO, President & Director |
Roy Lester Freeman | 70 | 2020 | Independent Director |
Valina L. Dawson | - | - | Member of Scientific Advisory Board |
Gisele Dion | 56 | 2022 | Independent Director |
Charles Warren Olanow | - | - | CEO of Clintrex Research Corporation & Member of Scientific Advisory Board |
Paul C. Grint | 65 | 2020 | Independent Director |
Karl Kieburtz | - | - | Member of Scientific Advisory Board |
Jeffrey H. Kordower | - | - | Member of Scientific Advisory Board |
Kenneth L. Marek | - | - | Member of Scientific Advisory Board |
Pankaj Jay Pasricha | - | - | Member of Scientific Advisory Board |
Robert A. Hauser | - | - | Member of Scientific Advisory Board |
Dennis N. Berman | 72 | 2020 | Independent Director |
Ted M. Dawson | - | - | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核